Sonja Hamed1, Bastian Schmack2, Florian Mueller1,2, Philipp Ehlermann1, Davina Hittmann1, Arjang Ruhparwar2,3, Hugo A Katus1,2, Philip W Raake1,3, Michael M Kreusser4,5. 1. Department of Internal Medicine III, Division of Cardiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. 2. Department of Cardiac Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. 3. DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany. 4. Department of Internal Medicine III, Division of Cardiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. michael.kreusser@med.uni-heidelberg.de. 5. DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany. michael.kreusser@med.uni-heidelberg.de.
Abstract
BACKGROUND: Ventricular assist devices (VAD) are increasingly used as long-term treatment for advanced heart failure. However, survival after VAD implantation is still unsatisfactory, and no specific outpatient follow-up algorithms have been formally established. Here, we evaluate the effect of an intensified follow-up protocol (IFUP) on survival rates and VAD-associated complications. METHODS AND RESULTS: This is a retrospective study of 57 patients who received a VAD at our center between February 2013 and December 2017. Inclusion criteria were discharge home after VAD implantation and follow-up in our VAD outpatient clinic. Patients implanted after October 2015 (n = 30) were monitored according to IFUP. This protocol embodied formalized, multi-disciplinary clinical visits every 4-8 weeks including a cardiologist, a cardiothoracic surgeon and a VAD-coordinator and was characterized by optimized anticoagulation and wound management as well as guideline-directed medical therapy. One-year survival in the IFUP patients was 97%, compared to 74% in the pre-IFUP era (p = 0.01). Implementation of IFUP was associated with a 90% risk-reduction for 1-year mortality (relative risk 0.099; p = 0.048). The rate of complications, e.g., device thrombosis and major bleeding, was significantly reduced, resulting in superior event-free survival in the IFUP group (p = 0.003). Furthermore, by implementation of IFUP, a more stable anticoagulation adjustment was achieved as well as an improved adherence to guideline-directed medical therapy. CONCLUSION: Implementation of an IFUP for VAD patients is associated with a significant decrease in 1-year all-cause mortality. This emphasizes the need for more vigilance in the management of VAD patients by a dedicated multi-disciplinary team.
BACKGROUND: Ventricular assist devices (VAD) are increasingly used as long-term treatment for advanced heart failure. However, survival after VAD implantation is still unsatisfactory, and no specific outpatient follow-up algorithms have been formally established. Here, we evaluate the effect of an intensified follow-up protocol (IFUP) on survival rates and VAD-associated complications. METHODS AND RESULTS: This is a retrospective study of 57 patients who received a VAD at our center between February 2013 and December 2017. Inclusion criteria were discharge home after VAD implantation and follow-up in our VAD outpatient clinic. Patients implanted after October 2015 (n = 30) were monitored according to IFUP. This protocol embodied formalized, multi-disciplinary clinical visits every 4-8 weeks including a cardiologist, a cardiothoracic surgeon and a VAD-coordinator and was characterized by optimized anticoagulation and wound management as well as guideline-directed medical therapy. One-year survival in the IFUP patients was 97%, compared to 74% in the pre-IFUP era (p = 0.01). Implementation of IFUP was associated with a 90% risk-reduction for 1-year mortality (relative risk 0.099; p = 0.048). The rate of complications, e.g., device thrombosis and major bleeding, was significantly reduced, resulting in superior event-free survival in the IFUP group (p = 0.003). Furthermore, by implementation of IFUP, a more stable anticoagulation adjustment was achieved as well as an improved adherence to guideline-directed medical therapy. CONCLUSION: Implementation of an IFUP for VAD patients is associated with a significant decrease in 1-year all-cause mortality. This emphasizes the need for more vigilance in the management of VAD patients by a dedicated multi-disciplinary team.
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: Alexander P Benz; Mate Vamos; Julia W Erath; Peter Bogyi; Gabor Z Duray; Stefan H Hohnloser Journal: Clin Res Cardiol Date: 2018-05-24 Impact factor: 5.460
Authors: Bastian Schmack; Alexander Weymann; Frank Ruschitzka; Rüdiger Autschbach; Philip W Raake; Nadine Jurrmann; Ares K Menon; Matthias Karck; Markus J Wilhelm; Arjang Ruhparwar Journal: Clin Res Cardiol Date: 2018-01-02 Impact factor: 5.460
Authors: Jasmin S Hanke; Günes Dogan; Amelie Zoch; Marcel Ricklefs; Leonhard Wert; Christina Feldmann; Christoph Bara; Malakh Shrestha; Jochen Tillmanns; Tibor Kempf; Johann Bauersachs; Axel Haverich; Jan D Schmitto Journal: J Thorac Cardiovasc Surg Date: 2018-02-13 Impact factor: 5.209
Authors: Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: Jeffrey J Teuteberg; Mark S Slaughter; Joseph G Rogers; Edwin C McGee; Francis D Pagani; Robert Gordon; Eduardo Rame; Michael Acker; Robert L Kormos; Christopher Salerno; Thomas P Schleeter; Daniel J Goldstein; Julia Shin; Randall C Starling; Thomas Wozniak; Adnan S Malik; Scott Silvestry; Gregory A Ewald; Ulrich P Jorde; Yoshifumi Naka; Emma Birks; Kevin B Najarian; David R Hathaway; Keith D Aaronson Journal: JACC Heart Fail Date: 2015-10 Impact factor: 12.035
Authors: Mandeep R Mehra; Yoshifumi Naka; Nir Uriel; Daniel J Goldstein; Joseph C Cleveland; Paolo C Colombo; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Ulrich P Jorde; Francis D Pagani; Keith D Aaronson; David A Dean; Kelly McCants; Akinobu Itoh; Gregory A Ewald; Douglas Horstmanshof; James W Long; Christopher Salerno Journal: N Engl J Med Date: 2016-11-16 Impact factor: 91.245
Authors: Katherine Lietz; James W Long; Abdallah G Kfoury; Mark S Slaughter; Marc A Silver; Carmelo A Milano; Joseph G Rogers; Yoshifumi Naka; Donna Mancini; Leslie W Miller Journal: Circulation Date: 2007-07-16 Impact factor: 29.690
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Anders Jorsal; Kasper Pryds; John J V McMurray; Henrik Wiggers; Anders Sommer; Jens Cosedis Nielsen; Roni Ranghøj Nielsen Journal: Clin Res Cardiol Date: 2019-09-26 Impact factor: 5.460
Authors: Michael M Kreusser; Sonja Hamed; Andreas Weber; Bastian Schmack; Martin J Volz; Nicolas A Geis; Leonie Grossekettler; Sven T Pleger; Arjang Ruhparwar; Hugo A Katus; Philip W Raake Journal: ESC Heart Fail Date: 2020-10-26